Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?

Camille Maadjhou Mba,1 Wilfred Mbacham,1 Eugène Sobngwi,2,3 Jean Claude Mbanya2,3 1Department of Physiological Sciences/Biochemistry, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon; 2Department of Internal Medicine and Special...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mba CM, Mbacham W, Sobngwi E, Mbanya JC
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://doaj.org/article/f434a57d7ab94f53a3ada0d9931ebba8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:f434a57d7ab94f53a3ada0d9931ebba8
record_format dspace
spelling oai:doaj.org-article:f434a57d7ab94f53a3ada0d9931ebba82021-12-02T05:15:57ZIs PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?1178-7007https://doaj.org/article/f434a57d7ab94f53a3ada0d9931ebba82019-12-01T00:00:00Zhttps://www.dovepress.com/is-pcsk9-associated-with-plasma-lipid-levels-in-a-sub-saharan-african--peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Camille Maadjhou Mba,1 Wilfred Mbacham,1 Eugène Sobngwi,2,3 Jean Claude Mbanya2,3 1Department of Physiological Sciences/Biochemistry, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon; 2Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon; 3National Obesity Center and Endocrine and Metabolic Diseases Unit, Yaoundé Central Hospital, Yaoundé, CameroonCorrespondence: Camille Maadjhou MbaDepartment of Physiological Sciences/Biochemistry, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, PO Box 1364, Yaoundé, CameroonEmail camilya91@yahoo.frPurpose: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of circulating LDL cholesterol. There are inconsistent data in some populations concerning the association between PCSK9, LDL and CRP. The emerging importance of the inhibition of PCSK9 for the treatment of hypercholesterolemia warrants investigations in different populations. The aim of this study from a Sub-Saharan African population was to evaluate the association between PCSK9 and hs-CRP levels and plasma lipid levels in patients with type 2 diabetes (T2D) and obese and lean controls.Patients and methods: A cross-sectional analytical study was conducted in a major hospital in Yaoundé, Cameroon in a cohort of 162 participants (53% females). There were 54 non-obese T2D patients matched for age and sex to 54 obese nondiabetic and 54 nondiabetic lean subjects. PCSK9 level was assessed by sandwich ELISA method and hsCRP by nephelometry.Results: PCSK9 and hs-CRP levels were significantly higher in obese and T2D subjects when compared to lean controls (pr=0.56, p=0.02 and r=0.2 and p=0.1, respectively). Multilinear regression analysis identified BMI as an independent predictor for PCSK9 levels and this association was maintained after adjustment for confounders; adjusted β-coefficient; 36.1 (95% CI; 29.2–47.4). We did not find an association between PCSK9 and any plasma lipid levels in obese and T2D subjects, nor between PCSK9 and hs-CRP levels.Conclusion: Obese and type 2 diabetes subjects have higher PCSK9 levels when compared to lean controls, suggesting that these metabolic states potentially impact PCSK9 levels in Cameroonian patients.Keywords: PCSK9, LDL-cholesterol, type 2 diabetes, obesityMba CMMbacham WSobngwi EMbanya JCDove Medical Pressarticlepcsk9ldl-cholesteroltype 2 diabetesobesitySpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 12, Pp 2791-2797 (2019)
institution DOAJ
collection DOAJ
language EN
topic pcsk9
ldl-cholesterol
type 2 diabetes
obesity
Specialties of internal medicine
RC581-951
spellingShingle pcsk9
ldl-cholesterol
type 2 diabetes
obesity
Specialties of internal medicine
RC581-951
Mba CM
Mbacham W
Sobngwi E
Mbanya JC
Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
description Camille Maadjhou Mba,1 Wilfred Mbacham,1 Eugène Sobngwi,2,3 Jean Claude Mbanya2,3 1Department of Physiological Sciences/Biochemistry, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon; 2Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon; 3National Obesity Center and Endocrine and Metabolic Diseases Unit, Yaoundé Central Hospital, Yaoundé, CameroonCorrespondence: Camille Maadjhou MbaDepartment of Physiological Sciences/Biochemistry, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, PO Box 1364, Yaoundé, CameroonEmail camilya91@yahoo.frPurpose: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of circulating LDL cholesterol. There are inconsistent data in some populations concerning the association between PCSK9, LDL and CRP. The emerging importance of the inhibition of PCSK9 for the treatment of hypercholesterolemia warrants investigations in different populations. The aim of this study from a Sub-Saharan African population was to evaluate the association between PCSK9 and hs-CRP levels and plasma lipid levels in patients with type 2 diabetes (T2D) and obese and lean controls.Patients and methods: A cross-sectional analytical study was conducted in a major hospital in Yaoundé, Cameroon in a cohort of 162 participants (53% females). There were 54 non-obese T2D patients matched for age and sex to 54 obese nondiabetic and 54 nondiabetic lean subjects. PCSK9 level was assessed by sandwich ELISA method and hsCRP by nephelometry.Results: PCSK9 and hs-CRP levels were significantly higher in obese and T2D subjects when compared to lean controls (pr=0.56, p=0.02 and r=0.2 and p=0.1, respectively). Multilinear regression analysis identified BMI as an independent predictor for PCSK9 levels and this association was maintained after adjustment for confounders; adjusted β-coefficient; 36.1 (95% CI; 29.2–47.4). We did not find an association between PCSK9 and any plasma lipid levels in obese and T2D subjects, nor between PCSK9 and hs-CRP levels.Conclusion: Obese and type 2 diabetes subjects have higher PCSK9 levels when compared to lean controls, suggesting that these metabolic states potentially impact PCSK9 levels in Cameroonian patients.Keywords: PCSK9, LDL-cholesterol, type 2 diabetes, obesity
format article
author Mba CM
Mbacham W
Sobngwi E
Mbanya JC
author_facet Mba CM
Mbacham W
Sobngwi E
Mbanya JC
author_sort Mba CM
title Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
title_short Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
title_full Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
title_fullStr Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
title_full_unstemmed Is PCSK9 Associated with Plasma Lipid Levels in a Sub-Saharan African Population of Patients with Obesity and Type 2 Diabetes?
title_sort is pcsk9 associated with plasma lipid levels in a sub-saharan african population of patients with obesity and type 2 diabetes?
publisher Dove Medical Press
publishDate 2019
url https://doaj.org/article/f434a57d7ab94f53a3ada0d9931ebba8
work_keys_str_mv AT mbacm ispcsk9associatedwithplasmalipidlevelsinasubsaharanafricanpopulationofpatientswithobesityandtype2diabetes
AT mbachamw ispcsk9associatedwithplasmalipidlevelsinasubsaharanafricanpopulationofpatientswithobesityandtype2diabetes
AT sobngwie ispcsk9associatedwithplasmalipidlevelsinasubsaharanafricanpopulationofpatientswithobesityandtype2diabetes
AT mbanyajc ispcsk9associatedwithplasmalipidlevelsinasubsaharanafricanpopulationofpatientswithobesityandtype2diabetes
_version_ 1718400507214561280